AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease

Subcutaneous SKYRIZI (risankizumab-rzaa) showed higher rates of endoscopic remission and ulcer-free endoscopy than placebo. The results build on previously reported week 12 findings in which SKYRIZI achieved superiority on co-primary clinical endpoints; the excerpt provides no effect sizes or event rates.